Business
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of TrueSite TI™, an industry-leading targeted integration (TI)-based CHO cell line platform designed to reshape biologics development by accelerating timelines, enhancing product quality, and ensuring consistent scalability for antibody and complex protein therapies.
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability.","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"The platform has achieved an average mAb titer exceeding 8.0 g/L with over 99% of clonal cell lines maintaining stable protein expression after passaging for 60 generations, which effectively mitigates the risk of titer drop during scale-up manufacturing to over 20,000 L.","length":282,"tagName":"p"}]},{"val":[{"type":"text","content":"It enables a 6-month IND timeline, accelerating development of innovative therapies and their path to commercial launch.","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"TrueSite TI™ has proved to be ideal for mAb development and demonstrated strong applicability to complex biologics, including bispecific antibodies (BsAb), Fc-fusion proteins, and Fab fragments.","length":199,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":784,"olType":false},{"type":"text","content":"SHANGHAI, Sept. 25, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of TrueSite TI™, an industry-leading targeted integration (TI)-based CHO cell line platform designed to reshape biologics development by accelerating timelines, enhancing product quality, and ensuring consistent scalability for antibody and complex protein therapies.","length":450,"tagName":"p"},{"type":"text","content":"Targeted integration is a precision-driven cellular engineering technique that enables the delivery of target expression units to predefined and rigorously validated locations in the host cells. Unlike conventional random integration or transposase methods, it streamlines development by limiting clone screening to just dozens of candidates, ensuring long-term expression stability, and significantly shortening IND timelines.","length":427,"tagName":"p"},{"type":"text","content":"TrueSite TI™ is the fourth generation of WuXi Biologics' proprietary WuXia™ cell line platform, an established system for generating high-titer, stable cell lines that has been technologically evolved and validated in over 1000 mo...